Cargando…

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Detalles Bibliográficos
Autores principales:	Yagisawa, Keiji, Kobayashi, Taku, Ozaki, Ryo, Okabayashi, Shinji, Toyonaga, Takahiko, Miura, Miki, Hayashida, Mari, Saito, Eiko, Nakano, Masaru, Matsubara, Hajime, Hisamatsu, Tadakazu, Hibi, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2020
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385572/ https://www.ncbi.nlm.nih.gov/pubmed/32713171 http://dx.doi.org/10.5217/ir.2018.00078-c1

Ejemplares similares

Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2019)

Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
por: Okabayashi, Shinji, et al.
Publicado: (2019)

Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome
por: Toyonaga, Takahiko, et al.
Publicado: (2017)

Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy
por: Saito, Daisuke, et al.
Publicado: (2018)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
por: Okabayashi, Shinji, et al.
Publicado: (2017)

Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease
por: Sagami, Shintaro, et al.
Publicado: (2019)

Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
por: Tamura, Satoshi, et al.
Publicado: (2020)

Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis
por: Kobayashi, Taku, et al.
Publicado: (2019)

Development of algorithms for identifying patients with Crohn’s disease in the Japanese health insurance claims database
por: Morikubo, Hiromu, et al.
Publicado: (2021)

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Inflammatory Bowel Disease in Japan -Is It Similar to or Different from Westerns?-
por: Okabayashi, Shinji, et al.
Publicado: (2020)

Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn’s Disease
por: Suzuki, Yasuo, et al.
Publicado: (2016)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease
por: Hisamatsu, Tadakazu, et al.
Publicado: (2017)

Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis
por: Saito, Daisuke, et al.
Publicado: (2021)

Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis
por: Sakuraba, Akihito, et al.
Publicado: (2021)

Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network)
por: Yamazaki, Hajime, et al.
Publicado: (2019)

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
por: Böhm, Stephan Karl, et al.
Publicado: (2014)

Lipocalin 2 prevents intestinal inflammation by enhancing phagocytic bacterial clearance in macrophages
por: Toyonaga, Takahiko, et al.
Publicado: (2016)

5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis
por: Wada, Haruka, et al.
Publicado: (2023)

Mesalazine-induced renal calculi
por: Jacobsson, Henrik, et al.
Publicado: (2013)

Myocarditis Related to the Use of Mesalazine
por: Kyriakou, Michaela, et al.
Publicado: (2023)

Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy
por: Takayama, Tetsuro, et al.
Publicado: (2015)

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
por: Hisamatsu, Tadakazu, et al.
Publicado: (2021)

Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2018)

Encapsulation of Hydrocortisone and Mesalazine in Zein Microparticles
por: Lau, Esther T. L., et al.
Publicado: (2013)

Randomised controlled trial of mesalazine in IBS
por: Barbara, Giovanni, et al.
Publicado: (2016)

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Yuichiro, Ohtaki, et al.
Publicado: (2022)

Colorectal Cancer Chemoprevention by Mesalazine and Its Derivatives
por: Stolfi, Carmine, et al.
Publicado: (2012)

Mesalazine-induced myocarditis: a case report
por: Radhakrishnan, Shiva T., et al.
Publicado: (2018)

Repurposing mesalazine against cardiac fibrosis in vitro
por: Hoffmann, Maximilian, et al.
Publicado: (2020)

Mesalazine-induced myopericarditis: a case report
por: Shergill, Simran
Publicado: (2020)

Analysis of clinical characteristics of mesalazine-induced cardiotoxicity
por: Chen, Junyu, et al.
Publicado: (2022)

Nanoparticles Obtained from Zein for Encapsulation of Mesalazine
por: Lima, Izabela Borges C., et al.
Publicado: (2022)

Mesalazine-induced myopericarditis: a case series
por: Andrei, Valentina, et al.
Publicado: (2023)

Enteral nutrition in the biologic era: learn from yesterday, live for today, hope for tomorrow
por: Hisamatsu, Tadakazu
Publicado: (2020)

Endoscopic Treatment of Colo-Colonic Intussusception in a Patient with Peutz-Jeghers Syndrome
por: Fujima, Takeshi, et al.
Publicado: (2023)

Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Ohtaki, Yuichiro, et al.
Publicado: (2023)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rptvvr8nd72nfvcb6u6gdjjmmi